Alexion other research news

Privately held Alexion (New Haven, Conn.) received two $75,000 Phase I SBIR grants from the NIH relating to regulation of the complement system.

Alexion will use the first grant to study the role that the complement cascade plays in the viability of platelets. The company will investigate the feasibility of using its complement inhibitors to halt platelet dysfunction caused by the activation of the complement cascade during platelet storage and circulation of blood through extracorporeal circuits. Extracorporeal circulation of blood is an integral component of hemodialysis and cardiopulmonary bypass procedures. ...